Lumicell
MA - NewtonBiotechnology
Focus: Lumicell is a newly founded (2024) biotech company specializing in cancer imaging device technology, with a commercial-stage fluorescence imaging system (LumiSystem) and lead therapeutic pegulicianine (LUMISIGHT) approved for intraoperative oncology applications.
Profile data last refreshed 16h ago · AI intelligence enriched 2w ago
Open Jobs
3+2 this month
Stable — net +2 jobs in 30d
3 added, 1 removed. Backfill posture.
Should You Work at Lumicell?
AI assessmentHigh-risk, high-upside pre-commercial oncology imaging play best suited for early-career scientists, commercial pioneers, or those seeking founder-stage equity exposure over near-term stability.
Why Work Here
- Early-stage opportunity with FDA-approved product (LUMISIGHT NDA, LOE 2034) and active commercial expansion at leading cancer centers as of Sept 2026.
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Growth7.8yr
Help build intelligence for Lumicell
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.